Garden Stage (NASDAQ:GSIW – Get Free Report) announced its quarterly earnings results on Friday. The company reported ($11.69) earnings per share (EPS) for the quarter, FiscalAI reports. The business had revenue of $1.94 million during the quarter.
Garden Stage Stock Performance
Shares of NASDAQ:GSIW opened at $21.00 on Friday. Garden Stage has a 12 month low of $8.00 and a 12 month high of $51.28. The company’s fifty day simple moving average is $28.13 and its 200 day simple moving average is $26.18.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings upgraded Garden Stage from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 8th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.
Hedge Funds Weigh In On Garden Stage
An institutional investor recently raised its stake in Garden Stage stock. XTX Topco Ltd boosted its position in shares of Garden Stage Limited (NASDAQ:GSIW – Free Report) by 244.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 258,052 shares of the company’s stock after purchasing an additional 183,147 shares during the period. XTX Topco Ltd owned about 0.72% of Garden Stage worth $33,000 at the end of the most recent reporting period. 0.47% of the stock is owned by institutional investors.
About Garden Stage
Garden Stage Limited, through its subsidiaries, provides securities dealing and brokerage, underwriting and placing, and other financial services in Hong Kong. It also offers asset management services comprising discretionary account management and fund management services. The company was incorporated in 2022 and is headquartered in Central, Hong Kong. Garden Stage Limited operates as a subsidiary of Oriental Moon Tree Limited.
Featured Stories
- Five stocks we like better than Garden Stage
- Popular’s Earnings Beat Shows Why This Bank Stock Keeps Climbing
- ABB’s Rotork Deal Could Put These Flow Control Stocks Back in Focus
- GE HealthCare Stock Climbs on Vital Diagnostics Demand
- Lost in Space: Why Aerospace Valuations Are Plummeting Right Now
Receive News & Ratings for Garden Stage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Garden Stage and related companies with MarketBeat.com's FREE daily email newsletter.
